Search results for 'pbio'
Pressure BioSciences Continues Strong Growth and Looks Ahead to More
On Tuesday, Pressure BioSciences, Inc. (OTC:PBIO) announced financial results for Q2 2012. For the second straight quarter, the maker of the patented Pressure Cycling Technology (PCT) Platform reported a revenue increase of approximately 70% over the same period last year. On the surface, this is a very positive sign for the company. After all, who
Pressure BioSciences (PBIO) Reports 70% Revenue Growth as Sales Expand
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game-changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen Inc. (NASDAQ: AMGN), recently reported a 70% increase in revenue growth. Last quarter, the company reported an 18% increase in PCT
Connecting the Dots in the Pressure BioSciences (PBIO) Story
We have written about Pressure BioSciences, Inc. (OTC:PBIO) from a variety of angles over the past few months, highlighting their distribution agreements and partnerships while talking about the impressive scientific validation of their Pressure Cycling Technology (PCT). This is an important time in the development of the company as they have moved from product development
Three Small Biotech Stocks with Big Potential
SpectraScience Inc. (OTCQB: SCIE), Pressure BioSciences Inc. (OTCQB: PBIO) and PositiveID Corporation (OTCBB: PSID) are three small biotech stocks with big potential. From cancer biopsies to sample preparation, these companies have developed products that revolutionize enormous industries representing billions of dollars in potential revenues. SpectraScience: Redefining Cancer Biopsy SpecraScience Inc. (OTCQB: SCIE) is a medical
Pressure BioSciences’ Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Advantages of the PCT Platform Could Potentially Enhance Development of New Products in the Forensic, Environmental, and Biodefense Areas, and in the Discovery of Biomarkers of Disease Pressure BioSciences, Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), providing equipment to companies like
Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Company Reiterates Guidance for Continued Strong Revenue Growth Throughout 2012 as its PCT Products Commercialization Plan Unfolds Pressure BioSciences, Inc. (OTC:PBIO) has developed patented technology that could significantly change and improve the way biological sample preparation is done. Having spent the last several years developing the products and garnering widespread recognition from the scientific community,
Pressure BioSciences (PBIO): Favorable Financing and Board Changes Signal Commercialization, Progress
Pressure BioSciences, Inc. (OTCQB: PBIO) is a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), which it provides to companies like Thermo Fisher Scientific (NYSE: TMO), Amgen Inc. (NASDAQ: AMGN) and other medical and biotechnology companies around the world. We have been following them for some
Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
Company Also Reduces Size of Board of Directors from Eight to Five and Announces Change in Board Membership, Including the Appointment of Life Sciences Industry Veteran Vito Mangiardi and Wall Street Veteran Kevin Pollack Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same
Pressure BioSciences (PBIO) Technology In-Depth
Pressure BioSciences, Inc. (OTCQB: PBIO) is a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), which it provides to companies like Thermo Fisher Scientific (NYSE: TMO), Amgen Inc. (NASDAQ: AMGN) and other medical and biotechnology companies around the world. What is Pressure Cycling Technology? Pressure BioSciences’ Pressure Cycling Technology
Pressure BioSciences (PBIO) Announces Strategic Partnership with LEAP Technologies
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same industry as companies like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX), recently announced a strategic co-development, co-marketing and co-selling agreement with well known LEAP Technologies, which is focused
Sample Preparation: A Rapidly Growing Industry
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same industry as companies like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX), recently announced a non-exclusive, worldwide, royalty-bearing license agreement. An Important & Growing Market Sample preparation before
Pressure BioSciences (PBIO) Deal Lauded by Zacks Research
Pressure BioSciences, Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen Inc. (NASDAQ: AMGN), was recently praised by Zacks Research for its favorable financing. According to Zack’s report on the topic, the key takeaway